ARRAY BIOPHARMA said FDA accepted its New Drug Application for binimetinib with a target action date under the Prescription Drug User Fee Act of June 30, 2017. Array completed its NDA submission of binimetinib in late Jun. 2016 based on findings from the phase III NEMO trial in patients with NRAS-mutant melanoma. jQuery(document).ready(function(){ jQuery('.people-thumb +...
Bits of good news for NIH flickered consistently over the past week.
